Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Paul Hudson

CEOPaul Hudson

Employees

84,587

Employees84,587

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

84,587

Employees84,587

SNY Key Statistics

Market cap

118.24B

Market cap118.24B

Price-Earnings ratio

11.84

Price-Earnings ratio11.84

Dividend yield

3.36%

Dividend yield3.36%

Average volume

3.45M

Average volume3.45M

High today

$48.10

High today$48.10

Low today

$47.72

Low today$47.72

Open price

$47.85

Open price$47.85

Volume

672.14K

Volume672.14K

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.62

52 Week low$44.62

SNY News

TipRanks 24h

Sanofi Advances Balinatunfib With New Cardiac Safety Study in Healthy Volunteers

Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools fo...

TipRanks 24h

Sanofi Targets Senior Flu Market With New Efluelda Safety Study in Korea

Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview Sanofi has launched a post‑marketing safet...

TipRanks 2d

Sanofi CEO says ‘aggressively’ looking for early-stage drug deals

Sanofi (SNY) CEO Paul Hudson made the comment while speaking at the JPMorgan healthcare conference. Claim 70% Off TipRanks Premium Published first on TheFly –...

More SNY News

Seeking Alpha 2d

Dynavax gains on disclosure another bidder interested after deal announced

Dynavax Technologies (DVAX) rose 1.9% after a disclosure that another bidder was interested in the company after it agreed to be sold to Sanofi (SNY) last month...

TipRanks 6d

Sanofi Advances Frexalimab With New Phase 3 Study of Subcutaneous vs. IV Dosing in Multiple Sclerosis

Sanofi SA (SNY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools fo...